# “Knockout Cancer”: The Impact of Adapted Boxing Training on Quality of Life in Breast Cancer Survivors, a Case Study

**Authors:** Claudia Cerulli, Arianna Murri, Damiano Zizzari, Cristina Rossi, Claudia Maggiore, Stefano Magno, Gianluca Franceschini, Ivan Dimauro, Attilio Parisi, Elisa Grazioli

PMC · DOI: 10.3390/jfmk11010071 · Journal of Functional Morphology and Kinesiology · 2026-02-10

## TL;DR

This case study explores how adapted boxing training can improve quality of life for breast cancer survivors.

## Contribution

The study introduces a novel, sport-specific boxing-based training protocol for breast cancer survivors.

## Key findings

- The boxing protocol was feasible and safe with high compliance and no serious adverse events.
- Participants showed improvements in functional tests, VO2max, and mobility/balance.
- One participant reported significant quality of life improvements, while the other showed mixed psychosocial outcomes.

## Abstract

Background: Exercise oncology research supports multicomponent interventions as complementary therapies to improve quality of life in breast cancer (BC) survivors. Nonetheless, evidence on sport-specific, engaging approaches, such as boxing-based concurrent training, remains scarce. Method: This case study aimed to evaluate the feasibility and safety, and to explore the effects of a 16-week adapted boxing protocol. Two BC survivors with a history of triple-negative BC in treatment were enrolled. The protocol integrated aerobic, strength/power, coordination, balance and boxing-specific exercises through individually adapted, progressive sessions performed twice a week. Outcomes were assessed pre- and post-intervention and included: (I) compliance and adverse event related to the protocol, (II) functional tests (handgrip, single leg stance, 30 s sit-to-stand, trunk/shoulder mobility tests, VO2max); (III) body composition parameters (fat mass, fat-free mass,); and (IV) validated questionnaires (EORTC QLQ-C30, FA12, PSQI, BIS, HADS, IPAQ). Results: Compliance was high and no serious adverse events were detected. Sit-to-stand performance, as well as VO2max and mobility/balance, improved in both patients after the intervention. Participant A showed a favorable body modulation. Participant B, on the other hand, reported a stable weight. Participant A reported large improvements across QLQ-C30 domains, while participant B exhibited mixed results, with improved emotional functioning and pain but declines in cognitive/social functioning. Conclusions: The boxing-based concurrent training protocol was feasible, safe, and well-tolerated. Despite the limitation of the case study, the observed functional and psychosocial positive changes highlight the need for adequately larger controlled trials to clarify the training protocol efficacy in order to optimize this exercise approach in BC survivors.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CXADRP1 (CXADR pseudogene 1) [NCBI Gene 653108] {aka CAR, CXADRP}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}
- **Diseases:** neurological disorders (MESH:D009461), Chronic fatigue (MESH:D015673), Hashimoto's disease (MESH:D050031), cognitive disorders (MESH:D003072), loss of muscle mass (MESH:C536030), lower back discomfort (MESH:D017116), limited joint mobility (MESH:D051346), invasive ductal carcinoma of the left breast (MESH:D018270), weight gain (MESH:D015430), lymph node (MESH:D000072717), loss of lean mass (MESH:D013851), orthopedic (MESH:D009140), autoimmune thyroiditis (MESH:D013967), nausea (MESH:D009325), heart failure (MESH:D006333), sinus tachycardia (MESH:D013616), loss of independence (MESH:D064129), BC (MESH:D001943), depression (MESH:D003866), chronic obstructive pulmonary disease (MESH:D029424), Cognitive fatigue (MESH:D005221), Scar tension (MESH:D002921), peripheral neuropathy (MESH:D010523), appetite loss (MESH:D001068), muscular failure (MESH:D051437), dyspnea (MESH:D004417), insomnia (MESH:D007319), Cancer (MESH:D009369), endocrine dysregulation (MESH:D004700), lymphedema (MESH:D008209), CF (MESH:D003550), Hospital Anxiety and Depression (MESH:D001007), injury to (MESH:D014947), inflammation (MESH:D007249), metastases (MESH:D009362), impaired balance and coordination (MESH:D001259), pain (MESH:D010146), hypertension (MESH:D006973)
- **Chemicals:** Cyclophosphamide (MESH:D003520), Water (MESH:D014867), Paclitaxel (MESH:D017239), levothyroxine sodium (MESH:D013974), TicheR (-), Epirubicin (MESH:D015251), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922093/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12922093/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922093/full.md

---
Source: https://tomesphere.com/paper/PMC12922093